Evidence for spontaneous, reversible paracyclophane formation. Aprotic solution structure of the boron neutron capture therapy drug, L-p-boronophenylalanine

Journal of the Chemical Society. Perkin Transactions 2

Volumn , Issue 3, 2000, Pages 557-561

  Shull, Brian K ^a   Spielvogel, David E ^a   Gopalaswamy, Ramesh ^a   Sankar, Sabapathy ^a   Boyle, Paul D ^a   Head, Gerald ^a   Devito, Kevin ^a  

^a Glycosyn Pharmaceuticals Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMINO ACIDS; AROMATIC COMPOUNDS; BORON; DIMERS; DRUG PRODUCTS; MOLECULAR DYNAMICS; MOLECULAR STRUCTURE; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; OLIGOMERS; ORGANIC ACIDS; PROTONS; THERMAL EFFECTS;

APROTIC SOLUTION; AROMATIC PROTONS; BORON NEUTRON CAPTURE THERAPY; BOROPHENYLALANINE; INTERMOLECULAR CHELATION; REVERSIBLE PARACYCLOPHANE FORMATION;

AMINES;

EID: 0034160965     PISSN: 03009580     EISSN: None     Source Type: Journal    
DOI: 10.1039/a906038c     Document Type: Article

References (56)

1. L. Deloux and M. Srebnik, Chem. Rev., 1993, 93, 763.
2. D. S. Matteson, Chem. Rev., 1989, 89, 1535.
3. (a) T. D. James, K. R. A. S. Sandanayake and S. Shinkai, Angew. Chem., Int. Ed. Engl., 1996, 35, 1910
4. (b) M. F. Paugam and B. D. Smith, Tetrahedron Lett., 1993, 34, 3723
5. (c) P. R. Westmark and B. D. Smith, J. Am. Chem. Soc., 1994, 116, 9343
6. (d) Z.-Y. Zhang and B. D. Smith, J. Am. Chem. Soc., 1998, 120, 7141 and references cited therein.
7. (a) J. D. Dunitz, D. M. Hawley, D. Miklos, D. N. J. White, Y. Berlin, R. Marusic and V. Prelog, Helv. Chim. Acta, 1971, 54, 1709
8. (b) H. Nakumura, Y. Iitaka, T. Kitahara, T. Okasaki and Y. Okami, J. Antibiot., 1977, 30, 714.
9. (a) A. B. Shenvi, Biochemistry, 1986, 25, 1286
10. (b) C. A. Kettner and A. B. Shenvi, J. Biol. Chem., 1984, 259, 15106
11. (c) C. N. Pace and R. A. Landers, Biochem. Biophys. Acta, 1981, 658, 410
12. (d) R. S. Reczkowski and D. E. Ash, Arch. Biochem. Biophys., 1994, 312, 31
13. (e) S. V. Khangulov, P. J. Pessiki, V. V. Barynin, D. E. Ash and G. C. Dismukes, Biochemistry, 1995, 34, 2015.
14. For recent reviews on BNCT, see: (a) A. H. Soloway, W. Tjarks, B. A. Barnum, R.-A. Rong, R. F. Barth, I. M. Codogni and J. G. Wilson, Chem. Rev., 1998, 98, 1515
15. (b) A. H. Beddoe, Br. J. Radiol., 1997, 70, 665
16. (c) M. F. Wawthorne, Angew. Chem., Int. Ed. Engl., 1993, 32, 950.
17. G. L. Lochner, Am. J. Roentgen. Rad. Ther., 1936, 36, 1.
18. (a) M. Javid, G. L. Brownell and W. H. Sweet, J. Clin. Invest., 1952, 31, 603
19. (b) W. H. Sweet, N. Engl. J. Med., 1951, 245, 875
20. (c) W. H. Sweet and M. Javid, J. Neurosurg., 1952, 9, 200.
21. (a) L. E. Farr, W. H. Sweet, J. S. Robertson, C. G. Foster, H. B. Locksley, D. L. Sutherland, M. L. Mendelsohn and E. E. Stickley, Am. J. Roentgenol., 1954, 71, 279
22. (b) J. T. Godwin, L. E. Farr, W. H. Sweet and J. S. Robertson, Cancer, 1955, 8, 601
23. (c) A. K. Asbury, R. G. Ojeann, S. L. Nielsen and W. H. Sweet, J. Neuropathol. Exp. Neurol., 1972, 31, 278.
24. R. F. Barth, A. H. Soloway and R. G. Fairchild, Cancer Res., 1990, 50, 1061.
25. H. Hatanaka, S. Kamano, K. Amano, S. Hojo, K. Sano, S. Egawa and H. Yasukochi, in Boron Neutron Capture Therapy for Tumors, ed. H. Hatanaka, Nishimura, Co., Ltd, Niigata, Japan, 1986, p. 349.
26. Y. Mishima, M. Ichihashi, M. Tsui, S. Hatta, M. Ueda, C. Honda and T. Suzuki, Lancet, 1989, 2, 388.
27. (a) M. Ichihashi, T. Nakanishi and Y. Mishima, J. Invest. Dermatol., 1982, 78, 215
28. (b) K. M. Yoshino, H. Okamoto, T. Kakihana, Y. Mori, Y. Mishima, M. Ichihashi, M. Tsuji and T. Nakanishi, in Proc. 2nd International Symposium on Neutron Capture Therapy, 1986, pp. 291-302.
29. (a) C. Honda, M. Shiono, N. Wadabayashi, M. Ichihashi, Y. Mishina, T. Koybayashi, K. Kanda, Y. Hori and K. Yoshino, in Progress in Neutron Capture Therapy for Cancer, eds. B. J. Allen, D. E. Moore, B. V. Harrington, Plenum Press, 1992, pp. 421-424
30. (b) J. Mallesch, D. E. Moore, B. J. Allen, W. H. McCarthy, R. Jones and W. A. Stening, in Advances in Neutron Capture Therapy, eds. A. H. Soloway, R. F. Barth, D. E. Carpenter, Plenum Press, 1993, pp. 735-738
31. (c) K. Matalka, R. Barth, A. Staubus, M. Moeschberger and J. Coderre, ibid., pp. 551-555
32. (d) Y. Mishima, M. Ichihashi, C. Honda, M. Shiono, T. Nakagawa, H. Obara, J. Shirakawa, J. Hiratsuka, K. Kanda, T. Kobayashi, T. Nozaki, O. Aizawa, T. Sato, H. Karashima, K. Yoshino and H. Fukuda, in Progress in Neutron Capture Therapy for Cancer, eds. B. J. Allen, D. E. Moore, and B. V. Harrington, Plenum Press, 1992, pp. 577-583
33. K. Z. Matalka, M. Q. Baily, R. F. Barth, A. E. Staubus, A. H. Soloway, M. L. Moeshberger, J. A. Coderre and E. K. Rofstad, Cancer Res., 1993, 53, 3308.
34. L. K. Mohler and A. W. Czarnik, J. Am. Chem. Soc., 1993, 115, 7037.
35. (a) Y. Mori, A. Suzuki, K. Yoshino and H. Kakihana, Pigment Cell Res., 1989, 2, 273
36. (b) Y. Yoshino, A. Suzuki, Y. Mori, H. Kakahana, C. Honda, Y. Mishina, T. Kobayashi and K. Kanda, Strahlenther. Onkol., 1989, 165, 127
37. (c) Y. Kinoshita, K. Yoshino, Y. Mori, H. Kakihan and Y. Mishima, in Progress in Neutron Capture Therapy for Cancer, eds. B. J. Allen, D. E. Moore, B. V. Harrington, Plenum Press, 1992, p. 243.
38. Replacing benzeneboronic acid with p-tolueneboronic acid (p-TBA) in Mohler and Czarnik's study, the complexation of alanine with p-TBA in DMSO provided up-field shifts of the aromatic protons from 7.67 (d, J = 7.3 Hz, 2H) and 7.13 (d, J = 7.3 Hz, 2H) to 7.32 (d, J = 8.0, 1H), 7.29 (d, J = 7.3 Hz, 1H) and 7.04 (v br d, 2H).
39. 2O shifts to 7.2 ppm in DMSO.
40. 1H NMR, thus, establishing this as as reversible process.
41. (a) F. Vögtle, Cyclophane Chemistry, John Wiley & Sons, West Sussex, England, 1993
42. (b) F. Diederich, Cyclophanes, The Royal Society of Chemistry, Cambridge, England, 1991
43. (c) F. Diederich, Cyclophanes, eds. P. M. Keehn and S. M. Rosenfield, Academic Press, New York, 1983.
44. R. H. Mitchell, in Cyclophanes, eds. P. M. Keehn, S. M. Rosenfield, Academic Press, New York, 1983, pp. 239-310.
45. Using CambridgeSoft's Chem3D software with ChemOffice Pro.
46. 3 where Δδ is the shift due to the influence of the aromatic ring, μ the value of the equivalent dipole (27.0 was used), θ the angle from the proton to the centroid perpendicular to the plane of the aromatic ring, and r the distance to the centroid, in Å see R. J. Abraham and P. Loftus, in Proton and Carbon-13 NMR Spectroscopy: An Integrated Approach, John Wiley & Sons, New York, 1978, pp. 19-23.
47. F. G. Bordwell, Acc. Chem. Res., 1988, 21, 463.
48. c.
49. J. Sandström, Dynamic NMR Spectroscopy, Academic Press, New York, 1982, p. 93.
50. (a) J. Sandström, Dynamic NMR Spectroscopy, Academic Press, New York, 1982, p. 1
51. H. S. Gutowsky and C. H. Holm, J. Chem. Phys., 1956, 25, 1228.
52. A. R. Katritzky, I. Ghiviriga, P. J. Steel and D. C. Oniciu, J. Chem. Soc., Perkin Trans. 2, 1996, 443.
53. P. Fischer and A. Fettig, Magn. Reson. Chem., 1997, 35, 839.
54. Only one X-ray crystal structure of an amino acid-boronic acid combination has been reported, albeit with the amino acid as its hydrochloride salt: R. Baggio, D. Elbaum, Z. Kanyo, P. J. Carroll, R. C. Cavalli, D. E. Ash and D. W. Christianson, J. Am. Chem. Soc., 1997, 119, 8107.
55. H. R. Snyder, A. J. Reedy and W. J. Lennarz, J. Am. Chem. Soc., 1958, 80, 835.
56. R. G. Bates and V. E. Bower, Anal. Chem., 1956, 28, 1322.